<DOC>
	<DOCNO>NCT01301456</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability PF-04856883 ( CVX-096 ) adult female subject Type 2 diabetes mellitus high dose metformin .</brief_summary>
	<brief_title>Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<criteria>History Type 2 diabetes currently treat high dose metformin BMI 22.0 40.0 kg/m2 HbA1c 7.010.0 % Fasting Cpeptide &gt; 1.21 ng/mL History clinically significant chronic condition Type 2 diabetes well control either diet medication Treatment antidiabetic therapy metformin History allergic anaphylactic reaction therapeutic diagnostic monoclonal antibody Males woman childbearing potential</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>CVX-096</keyword>
</DOC>